Four-week total IgE/baseline total IgE ratio: Biomarker for omalizumab good response in chronic spontaneous urticaria real-life patients

Omalizumab (anti-IgE antibody) is an effective and well-tolerated treatment option for H1-antihistamine refractory chronic spontaneous urticaria (CSU) patients.1 Response predictors remain incompletely defined. Because omalizumab target is IgE, it has been hypothesized that IgE levels may be associated with the effects of this treatment.2 Therefore, we aimed to broaden current knowledge of the potential role of baseline total IgE (bIgE) and the ratio of 4-week total IgE (w4IgE)/bIgE in response prediction in CSU.